Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2021

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
MedSurg	$	917	$	825	$	2,725	$	2,175
Rhythm and Neuro	819		757		2,436		1,985
Cardiovascular	1,196		1,002		3,588		2,862
Total net sales of reportable segments	2,932		2,584		8,748		7,021
All other (Specialty Pharmaceuticals)(1)	—		74		13		183
Net sales	$	2,932	$	2,659	$	8,761	$	7,204


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020


MedSurg	$	338	$	307	$	1,033	$	738
Rhythm and Neuro	160		165		476		296
Cardiovascular	361		208		1,117		593
Total operating income of reportable segments	859		680		2,626		1,628
All other (Specialty Pharmaceuticals)(1)	—		49		4		124
Unallocated amounts:
Corporate expenses, including hedging activities	(109)		(108)		(438)		(330)
Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), and certain litigation-related net charges (credits) and EU MDR implementation costs	(178)		(629)		(624)		(957)
Amortization expense	(184)		(197)		(549)		(595)
Operating income (loss)	387		(205)		1,019		(130)
Other expense, net	95		(22)		(62)		(256)
Income (loss) before income taxes	$	483	$	(227)	$	957	$	(386)

(1) On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Our consolidated net sales and income (loss) before income taxes for the first nine months of 2021 include Specialty Pharmaceuticals up to the date of the closing of the transaction.


Operating income margin of reportable segments	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
MedSurg	36.8	%	37.2	%	37.9	%	33.9	%
Rhythm and Neuro	19.5	%	21.9	%	19.5	%	14.9	%
Cardiovascular	30.2	%	20.8	%	31.1	%	20.7	%